GO
Loading...

Pharmaceuticals

More

  • ImClone's New CEO: Already Repeating The Past? Wednesday, 12 Sep 2007 | 2:26 PM ET

    Recently I blogged about the hiring of a new CEO at ImClone Systems and the unique clause in his contract requiring him to buy half-a-million dollars worth of stock in the company. My suspicion was that ImClone Chairman and billionaire shareholder Carl Icahn had a hand in that.

  • Drug Pipeline Picking Up Wednesday, 12 Sep 2007 | 1:11 PM ET

    There’s a ton of Big Pharma and Biotech news coming out. And most of it reinforces the call from the Fast Money traders to buy these stocks heading into the end of this year.

  • Biovail Case: The Reply From A David Maris Lawyer Wednesday, 12 Sep 2007 | 10:52 AM ET

    Yesterday, I blogged that messages to each of David Maris' lawyers seeking comment on Biovail "dropping" or "settling" its case against the former Bank of America Securities analyst had gone without a response. Well, this morning I got this email from one of his attorneys tossing the ball back in Biovail's court:

  • ImClone, Merck Shares Jump on Erbitux Trial Tuesday, 11 Sep 2007 | 12:41 PM ET

    The cancer drug Erbitux unexpectedly extended survival in a trial of patients with advanced lung cancer, sending shares of its maker, ImClone Systems, soaring as much as 24 percent.

  • Medicare Urged to Reimburse More for Anemia Drugs Tuesday, 11 Sep 2007 | 12:36 PM ET

    Is the Senate coming to the rescue of patients, investors or both? That's the question being raised after the passage of a non-binding resolution telling Medicare to "immediately reconsider" its new policy to cut anemia drug use and reimbursement. Analysts are stunned by the move.

  • Biovail Not Dropping Lawsuit(s) After All? Tuesday, 11 Sep 2007 | 11:44 AM ET

    A follow-up to my post yesterday about the New York Post story regarding Biovail "dropping" its lawsuits alleging collusion to beat down its stock. This email showed up in the blog inbox this morning..."Your report on Biovail is not accurate..."

  • FDA Meetings And Latest On Biotech Front Tuesday, 11 Sep 2007 | 10:59 AM ET

    So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.

  • Stocks Get a Lift, Street on Fed Watch Tuesday, 11 Sep 2007 | 8:53 AM ET

    Wall Street is counting down to next week's Fed meeting and not much else is influencing trading. Stocks are readying for a higher opening as investors wait for a speech from Fed Chairman Ben Bernanke later this morning and watch the action at OPEC.

  • Roche Sues Teva in U.S. Over Bone Drug Tuesday, 11 Sep 2007 | 5:08 AM ET

    Swiss drugmaker Roche Holding is taking legal action against Israel's Teva Pharmaceutical Industries in the United States to prevent Teva from selling a generic version of Roche osteoporisis drug Boniva, Roche said on Tuesday.

  • Biovail Ends Lawsuit As Investigations Continue Monday, 10 Sep 2007 | 4:22 PM ET

    The New York Post broke the news today that Biovail Corporation, Canada's biggest biotech, is dropping its lawsuit against a hedge fund, a research outlet, Bank of America Securities and its former specialty pharmaceuticals analyst David Maris. "60 Minutes" did a piece on the lawsuits last year. Shortly after being sued, Maris left B of A. He and the company never disclosed..

  • Byetta: What We Know Right Now Monday, 10 Sep 2007 | 3:36 PM ET

    For some time now I've been occasionally blogging about the data on a once-a-week version of Byetta that are expected in the fourth quarter sometime. This is a long-acting release (LAR, for short) version of the current twice-a-day injectable drug for diabetes from Lilly and Amylinspacer. Alkermes makes the technology that extends the drug's release.

  • Isis, Alnylam (Shazam!) Create Regulus Friday, 7 Sep 2007 | 11:59 AM ET
    Leo Regulus

    Call it a stellar, mythic merger. This morning Isis Pharmaceuticals (named after the goddess in Egyptian mythology) and Alnylam Pharmaceuticals (named after the center star in Orion's belt) announced they're forming a joint venture called Regulus Therapeutics, LLC (named after the brightest star in the constellation Leo). I'm sensing a theme here.

  • Amylin's Byetta LAR: Wait Is On For Results Thursday, 6 Sep 2007 | 4:08 PM ET

    An update from the NewsMakers in Biotech conference in NYC on an item of intense interest. Amylin Pharmaceuticals just held a well-attended PowerPoint presentation followed by a very cramped breakout session. And pretty much the only thing investors and analysts wanted to talk about is Byetta LAR (long-acting release).

  • Biotech Conference: Hoping For A Repeat Year Thursday, 6 Sep 2007 | 11:21 AM ET

    Blogging from the 14th NewsMakers in the Biotech Industry conference put on by BioCentury and Thomson Financial in Manhattan. It's a rare opportunity to spend a day getting possible story ideas and networking with sources.

  • Drugmaker AstraZeneca said on Thursday it had seen strong demand for $6.9 billion of bonds it issued to repay a significant part of the U.S. commercial paper taken on for the acquisition of biotechnology company Medimmune.

  • Pfizer Comes Out Swinging On Lipitor Wednesday, 5 Sep 2007 | 11:02 AM ET
    Lipitor

    The gloves are off. Overnight, Pfizer came out with a new study on the world's top-selling drug, Lipitor, for cholesterol. The company says if you switch from its drug to generic Zocor you've got a 30% greater chance of dying from a heart attack, stroke or some other "major cardiovascular" event.

  • Pfizer: I'm Reporting Layoffs? That's News To Me Tuesday, 4 Sep 2007 | 2:18 PM ET

    As I was gearing up to come back to work from my extended holiday weekend I searched some of my mainstay internet sources for information and tips yesterday including cafepharma.com. It's filled with pharmaceutical and biotech company message boards with postings mostly from sales reps complaining, providing job applicants with salary and benefits details, occasionally revealing the latest internal memo, and frankly, spreading rumors and gossip.

  • Dendreon Provenge, Pfizer's Viagra Ads: Your Emails Wednesday, 29 Aug 2007 | 1:28 PM ET

    I'll be out of the office for an extra-long holiday weekend, so I'm emptying out the blog inbox before I go. Nick Stavriotis sent an email to clarify his previous incomplete statement regarding the FDA's "overrule" of the Dendreon Provenge advisory committee recommendation: "...my words should have said 'refusal to follow an overwhelming...

  • Xoma Comes Alive! (With Help From Pfizer) Tuesday, 28 Aug 2007 | 1:17 PM ET

    Xoma Ltd., the subject of a prominent, front page New York Times Sunday Business section article earlier this year headlined, "It's Alive! One of Biotech's Zombies", is leaving the Zombies behind. The shares of the small cap are up more than 20% on heavy volume. The Times piece described how the 26-year-old company had yet to turn a profit (the overwhelming majority of biotechs don't make money),

  • Merck's Gardasil For Boys: How Will Those Ads Play? Monday, 27 Aug 2007 | 2:51 PM ET
    Gardasil

    We've known that Merck has been testing its cervical cancer vaccine Gardasil on young men (16-23 years old). The company says major data on those clinical trials are expected next year and could help Merck win FDA approval of the shots for males as well as females. The first-of-its-kind product has already sparked a sociopolitical controversy with its recommended use for young women. Imagine the brouhaha if or when Merck starts selling it for young men.